Bachem Rises on Technique for Producing Interferon: Zurich Mover

Bachem Holding AG posted its biggest gain in a year after the Swiss maker of pharmaceutical ingredients said it found a simpler way to make a multiple sclerosis drug with a global market of more than $4 billion.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.